MMJ PhytoTech Ltd (ASX:MMJ) is pleased to advise that the Company's Australian distribution partner, HL Pharma Pty Ltd. has submitted its application for a medicinal cannabis import licence to the Department of Health.
Lexaria Bioscience Corp. (OTCMKTS:LXRP) (CSE:LXX) is pleased to announce it has received a Notice of Acceptance from the Australian Patent Office that Lexaria's Australian patent application 2015274698 has been accepted with a patent issuance date expected in June, 2017.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that Canadian-based Harvest One Capital Corp. (CVE:WON.H) has closed the previously reported (January 27, 2017) private placement, raising C$25,000,500 before costs. Pursuant to the Placement, Harvest One issued 33,334,000 Subscription Receipts at a price of C$0.75.
Imugene Limited (ASX:IMU) preclinical research related to HER-Vaxx (clinical name IMU-131) has been accepted and published in the prestigious journal BMC Cancer. IMU-131 is a next generation HER-2 cancer therapy using B cell peptides, which harness the body's ability to develop antibodies against the disease.
MMJ PhytoTech Ltd (ASX:MMJ) is pleased to advise that it has entered into a binding Letter of Intent with HL Pharma Pty Ltd. for the importation and distribution of the Company's medicinal cannabis products in Australia.
MMJ PhytoTech Ltd (ASX:MMJ) is pleased to advise that its wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited ("PTL"), has commenced following Health Authorities' approval, the Phase 2 clinical study into the safety and efficacy of its PTL101 capsules in treating refractory epilepsy in children.
Lifespot Health Ltd (ASX:LSH) is pleased to announce that its 100% owned subsidiary, BodyTel GmbH and Roche Diagnostics Deutschland GmbH, have signed an agreement to integrate Roche's newly developed Bluetooth enabled PT/INR device 'CoaguChek(R) INRange' into BodyTel's telemedical platform.
